Honey is said to help with hay fever symptoms – here’s what the research says about this claim 
Does ejaculating often reduce your risk of prostate cancer? 
Can a drug like Ozempic help treat addictions to alcohol, opioids or other substances? 
Synthetic human embryos let researchers study early development while sidestepping ethical and logistical hurdles 
A Nasa rover has reached a promising place to search for fossilised life on Mars 
Orbital resonance − the striking gravitational dance done by planets with aligning orbits 
Gut microbiome: meet Clostridium butyricum – the bacteria that helps keep us feeling our best 
Tapeworm larvae found in man’s brain – how did they get there? 
The hidden racist history of hair loss 
Larger and more frequent solar storms will make for potential disruptions and spectacular auroras on Earth 
Spacesuits need a major upgrade for the next phase of exploration 
If life exists on Jupiter’s moon Europa, scientists might soon be able to detect it 
Tatahouine: 'Star Wars meteorite' sheds light on the early Solar System 
How do airplanes fly? An aerospace engineer explains the physics of flight 
Genetic diseases: How scientists are working to make DNA repair (almost) a piece of cake 
Eye infections might seem like a minor complaint – but in some cases they can cause blindness and even death 
The cure for cancer has been one of the highest priorities of the medical world for decades, with scientists in both private and public fields trying their best to finally rid the world of the deadly disease. One group is closing in on a cure after publishing a paper indicating that they were able to reverse the conditions of terminally ill patients.
It’s well-known within the cancer community that the best way to head off cancer with current treatments is early diagnosis and an aggressive few rounds of chemotherapy, among other treatments. Once a patient reaches stage 4, their chances of survival diminish considerably. The US-based pharmaceutical company Kite Pharma is working on changing that and is making considerable headway.
The work that the company’s researchers were doing involve gene therapy and the trials yielded results that included terminally-ill patients going into remission after they were treated to just one round of trials. The trial itself lasted six months, with numerous subjects injected with modified T-cells.
For those who don’t know, T-cells are basically immune cells that are meant to destroy harmful invaders in the body. The genius of cancer cells is their ability to evade T-cells, which allows them to spread all over the body and multiply.
By genetically engineering these immune cells in order to make them more effective patrollers, they become better equipped to identify and eliminate cancer cells, Futurism reports. As a result, even patients who are at an advanced stage of the disease have a chance of cleansing their body of the illness.
As for the patients involved in the trials, they were divided based on which of the three types of non-Hodgkin lymphoma they had. Due to how advanced the stage of the cancer was in their bodies, most of the subjects were only given a few months to live. After the trials, many were given a second chance at life.
